Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis

Eur J Med Chem. 2021 Jan 15:210:112983. doi: 10.1016/j.ejmech.2020.112983. Epub 2020 Oct 31.


This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF.

Keywords: CINODs; COX-2; Cystic fibrosis; Inflammation.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase 2 Inhibitors / chemistry
  • Cyclooxygenase 2 Inhibitors / pharmacology*
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / metabolism
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Molecular Structure
  • Nitric Oxide / chemistry
  • Nitric Oxide / pharmacology*


  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Nitric Oxide
  • Cyclooxygenase 2